Galmed Pharmaceuticals Ltd

GPH

Company Profile

  • Business description

    Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

  • Contact

    16 Tiomkin Street
    Tel Aviv6578317
    ISR

    T: +972 36938448

    E: [email protected]

    https://www.galmedpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    8

Stocks News & Analysis

stocks

Competition impacting ASX market darling

Shares tumble after results.
stocks

Ask the analyst: Is the market underestimating Bapcor?

This moated ASX company's shares are in a prolonged slump. I quizzed our analyst Angus Hewitt on its management, the potential impact of EVs, and more.
stocks

Is our ASX best idea still attractive after shares surge?

Shares rose over 21% following the results. 

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,752.504.900.06%
CAC 408,006.2233.190.42%
DAX 4021,911.74124.740.57%
Dow JONES (US)44,470.41167.010.38%
FTSE 1008,767.8067.270.77%
HKSE21,395.73126.25-0.59%
NASDAQ19,714.27190.870.98%
Nikkei 22538,801.1714.150.04%
NZX 50 Index12,917.4541.100.32%
S&P 5006,066.4440.450.67%
S&P/ASX 2008,485.002.200.03%
SSE Composite Index3,316.835.34-0.16%

Market Movers